Tempest Therapeutics, Inc. (NasdaqCM: TPST)
Health Care · Biotechnology · US
$1.11
+6.73% today · -90.2% 1Y
Tempest Therapeutics, Inc. (NasdaqCM: TPST) operates in the Biotechnology industry within the Health Care sector. The company is valued at $16.62M and employs 4 people.
Over the last twelve months the share price has lost 90.2%, trading between 0.84 and 12.23.
Tweenvest scores Tempest Therapeutics, Inc. across four factors: quality 12/100. Its strongest factor is quality.
TPST price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $16.62M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.56
- Dividend yield
- —
- Beta (5Y)
- -1.68
- 52-week high
- $12.23
- 52-week low
- $0.84
- Avg volume (3M)
- —
- Shares outstanding
- 15.98M
- Employees
- 4
- Next earnings
- —
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
- ISIN
- US87978U2078
- Listed since
- Nov 12, 2012
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.29 | +0.67% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.18 | +0.08% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.42 | +1.14% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $553.77 | +1.13% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $834.60 | +0.74% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $156.25 | +12.50% |
Figures last refreshed Aug 18, 2026.